- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| BRIDGEBIO ONCOLOGY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.09. | Stifel cuts BridgeBio Oncology price target on pipeline shift | 1 | Investing.com | ||
| 08.09. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 14 | SEC Filings | ||
| 08.09. | BridgeBio Oncology Therapeutics, Inc.: BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers | 319 | GlobeNewswire (Europe) | BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patientsBBO-8520 monotherapy continues to show highly competitive... ► Artikel lesen | |
| 11.08. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 11.08. | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress | 640 | GlobeNewswire (Europe) | Continued to advance monotherapy and combination cohorts for all clinical programsInitiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of... ► Artikel lesen | |
| 11.08. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.07. | JPMorgan startet Coverage für BridgeBio Oncology mit "Overweight"-Rating | 2 | Investing.com Deutsch | ||
| 08.07. | JPMorgan initiates BridgeBio Oncology stock with overweight rating | 2 | Investing.com | ||
| 22.06. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | Oppenheimer initiates BridgeBio Oncology stock rating at Outperform | 1 | Investing.com | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$526.11 | 2 | Seeking Alpha | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress | 552 | GlobeNewswire (Europe) | Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818... ► Artikel lesen | |
| 12.05. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 29.04. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | BridgeBio Oncology presents preclinical data on KRAS inhibitor | 10 | Investing.com | ||
| 22.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 22.04. | BridgeBio Oncology Therapeutics appoints new CEO and COO | 3 | Seeking Alpha |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 15,460 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,170 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DISC MEDICINE | 60,48 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| COGENT BIOSCIENCES | 29,780 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| QIAGEN | 40,535 | +0,86 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,960 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| EVOTEC | 2,460 | -11,13 % | AKTIEN IM FOKUS: Aktien aus Diagnostik- und Laborbranche gesucht | FRANKFURT (dpa-AFX) - Aktien aus dem Segment Wirkstoffforschung, Diagnostik und Laborausrüstung haben am Dienstag auf den Kauflisten von Anlegern gestanden. Den Dax führten die Papiere von Qiagen und... ► Artikel lesen | |
| MODERNA | 191,12 | -0,13 % | Community Rückblick: wO-User zum Kurssturz bei Newron Pharma: "Der Wirkstoff ist - Stand jetzt - tot" | © Foto: Newron Pharmaceuticals SpAFDA-Schock bei Newron Pharma: Nach dem Kurssturz entbrennt im wO-Forum eine hitzige Debatte über Todesfälle, Managementkommunikation und die Zukunft des Hoffnungsträgers... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 8,565 | 0,00 % | Why Is Contineum Therapeutics Stock Falling Monday? | ||
| RECURSION PHARMACEUTICALS | 4,005 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| MBX BIOSCIENCES | 52,02 | 0,00 % | Stifel raises MBX Biosciences price target to $84 on obesity drug data | ||
| IMMUNOVANT | 29,470 | -0,03 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,145 | +0,09 % | AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics | ||
| PRAXIS PRECISION MEDICINES | 251,25 | -0,05 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| PARABILIS MEDICINES | 28,950 | 0,00 % | Parabilis Medicines, Inc.: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates | Advanced zolucatetide across multiple Wnt/ß-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with... ► Artikel lesen |
Das Unternehmen BRIDGEBIO ONCOLOGY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,15 % bei einem Aktienkurs von 3,255 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRIDGEBIO ONCOLOGY THERAPEUTICS INC finden Sie auf Wallstreet Online.